Canada - Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry

Since 2014, Canada Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry increased 2.3% year on year. In 2019, the country was number 17 comparing other countries in Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry at $420,159,373.17 Million PPP. Canada is overtaken by Hungary, which was ranked number 16 with $426,636,826.27 Million PPP and is followed by Ireland with $407,799,563.58 Million PPP. United States topped the ranking with $70,565,318,932.39 Million PPP in 2019, that is a growth of 3.3% versus 2018. China, Japan and Germany respectively ranked number 2, 3 and 4 in this ranking. Iceland witnessed the best average annual growth at +43.9% per year, while Lithuania was the worst growing country at -42.6% per year.

Loading...

Date Million US Dollars PPP
2019 420,159,373.17
2018 427,220,978.12
2017 455,701,557.85
2016 410,992,641.87
2015 400,639,663.21
Download all data from 1994 to 2019

How does Canada rank in Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry?

# 69 Countries Million US Dollars PPP Last YoY 5‑years CAGR
1 #1
United States
70,565,318,932.39 2019 +3.3 % +4.5 % View data
2 #2
China
13,956,388,273.35 2019 +4.5 % +6.1 % View data
16 #16
Hungary
426,636,826.27 2019 +1.7 % -0.3 % View data
17 #17
Canada
420,159,373.17 2019 -1.6 % +2.3 % View data
18 #18
Ireland
407,799,563.58 2019 +3.8 % +16.9 % View data
Compare all 69 countries

Go Top